đŹ BEHIND THE SCENE – Corinne TORTORELLI, Sr Lead Medical Affairs
đŹ BEHIND THE SCENE – Corinne TORTORELLI (PharmD, Ph.D) Plongez dans lâaventure, racontĂ©e par celles et ceux qui la vivent. SEE VIDEO Dans cette interview, Corinne partage son parcours ; et ce qui lâa motivĂ©e Ă rejoindre Brenus Pharma pour la suite de sa carriĂšre en #oncologie, en tant que Sr Lead Medical Affairs. Toujours prĂȘte Ă relever les challenges elle sâimplique au quotidien dans la #coconstruction de projets Ă rĂ©elle valeur ajoutĂ©e pour amĂ©liorer la prise en charge des #patients atteints dâun cancer. đ„đĄ âĄïžIn this interview, Corinne shares her professional journey and what motivated her to join Brenus Pharma for the next phase of her career in #oncology as Sr Lead Medical Affairs. Corinne is always ready to take on challenges and actively engages in the co-creation of projects that bring real value to enhance the care of cancer patients. #BehindTheScene #DareToInnovate CrĂ©dit vidĂ©o : https://lets-up.fr/ đCardinal Workside 60 Quai Perrache 69002 – LYON (FR)
Join us at BIO Europe Spring
đą Last chance to schedule a meeting and connect with our CEO Paul Bravetti, at BIO- Europe Spring convention next week. hashtag#BES24 đą âĄïž A good opportunity to find out the recent achivements we made and the upcoming clinical development plan. Click here : https://lnkd.in/eudjdypq BIO-Europe Spring, the premier springtime partnering event takes place in Barcelona [18-20 March] and brings key biopharma actor to elevate life science partnerships. hashtag#Biotech hashtag#Innovation hashtag#Immunotherapy hashtag#STCPlatform hashtag#collaborations Voir la traduction
[đą5M⏠to obtain safety and efficacy clinical data in colorectal cancer đ]
DOWNLOAD PR đ Brenus Pharma winner of the call for proposals hashtag#FRANCE2030 : 5M⏠to obtain safety and efficacy clinical data in colorectal cancer đ Nous sommes fiers d’annoncer que Brenus Pharma a Ă©tĂ© dĂ©signĂ©e laurĂ©ate de l’appel Ă projet “Innovations en biothĂ©rapies et bioproduction” du programme France 2030. âĄïžCe financement majeur de prĂšs de 5 millions d’euros vise Ă accĂ©lĂ©rer la bioproduction et lâindustrialisation du STC-1010, nouvelle hashtag#immunothĂ©rapie cellulaire et vaccinale guidĂ©e par hashtag#protĂ©omique mise au point pour aider le systĂšme immunitaire Ă lutter contre les tumeurs rĂ©sistantes. đCe soutien financier va ainsi permettre dâobtenir les premiĂšres donnĂ©es dâefficacitĂ© et de sĂ©curitĂ© chez lâHomme, du vaccin visant le cancer colorectal mĂ©tastatique. (mCRC) đŻTĂ©lĂ©charger le communiquĂ© ici / Dowload press release here https://lnkd.in/ePfkh3qy Cette distinction de lâĂtat et Bpifrance valide notre engagement envers l’innovation et souligne notre rĂŽle dans l’avancement de la recherche française en biothĂ©rapie : « Brenus Pharma se distingue par sa plateforme innovante qui gĂ©nĂšre de nouvelles immunothĂ©rapies cellulaires et vaccinales guidĂ©es par protĂ©omique. Ces thĂ©rapies sont basĂ©es sur la reproduction in vitro des signatures protĂ©omiques des tumeurs rĂ©sistantes. Cette innovation nous permet dâĂ©duquer le systĂšme immunitaire des patients Ă reconnaĂźtre et cibler ces mĂ©canismes de rĂ©sistance qui Ă©chappent habituellement Ă sa surveillance. Nous remercions lâEtat via France 2030 pour ce soutien qui valide lâapproche technologique de Brenus et devrait permettre dâaccĂ©lĂ©rer sa mise Ă disposition aux patients. » dĂ©clare Paul Bravetti, directeur gĂ©nĂ©ral. Merci Ă hashtag#FRANCE2030 ; Bpifrance pour votre confiance et Ă tous ceux qui nous ont accompagnĂ©s LyonbiopĂŽle Auvergne-RhĂŽne-Alpes ; MabDesign Network; France Biotech, EFS Plus dâinformations sur : france2030.gouv.fr | https://lnkd.in/e-zECrMJ | @SGPI_avenir et www.Bpifrance.fr â www.presse.bpifrance.fr â hashtag#Colorectalcancer hashtag#clinical hashtag#BPIFrance hashtag#cancervacinne hashtag#Biotechnology hashtag#Biotech hashtag#Healthcare
Hybridays 2024
Corinne Tortorelli & LĂ©a Perles had the honor last week of participating as a talented #Biotech in the 2nd edition of the #Hybridays dedicated this year to “the next generations of gene and cell therapies”. High-quality expert reviews, strategic discussions during round tables as well as rich discussions (B2B) with stakeholders in the eco-system reinforced our conviction that Brenus Pharma with its immunotherapy platform would participate in the coming years to strengthen the care of hashtag#cancerpatients whose current needs are not covered. #Bioproduction #Biotherapie #Innovation France Biotech Bpifrance ariis – Alliance Recherche Innovation Industries SantĂ©
Join us at PSCC Innovation Forum 2024
Today, the Paris Saclay Cancer Cluster kicks off its inaugural “Innovation Forum 2024” at the Faculty of Medicine Paris-Saclay. đ We’re excited to start this day dedicated to scientific discoveries, engaging exchanges, and fostering collaboration within our ecosystem. đ€ We look forward to meet experts, researchers, industry professionals, start-ups, patients, platform developers… in the fight against cancer. Let’s share this moment of science, connections, and conviviality! hashtag#PSCCInnovationForum hashtag#CancerResearch hashtag#ScienceCommunity UniversitĂ© Paris-Saclay, Sanofi, Inserm, Institut Polytechnique de Paris, Gustave Roussy, Institut Curie, AP-HP, Assistance Publique – HĂŽpitaux de Paris, Unicancer, HĂŽpitaux Saint-Joseph & Marie-Lannelongue, Hopital Foch
đ Project Update | Allogenix Consortium đ
đ Project Update | Allogenix Consortium đ Our Oncology and Immunology team spent a productive day with our đ€ partners from InSphero, during which they discussed the progress of the joint Allogenix consortium. đ Launched in November 2022 with a duration of 3 years, the project, funded by the #EUROSTARS Programme, aims to develop a companion test for the next-generation cancer cell #immunotherapy STC-1010. âïžSTC-1010 is the 1st asset from Brenus Pharma‘s unique STC “off-the-shelf” discovery platform (Stimuated-Tumor-cells : Shared Stimulated & Haptenized Cancer related proteins) targeting #colorectalcancer đ€© We are thrilled to report promising preliminary results, which have fuelled the advancement to the next development stage. đ€ It’s a true pleasure collaborating with the experts from InSphero, as we work together to pursue the ambitious goal of developing aâïžfirst-in-class allogeneic cell vaccine against cancerâïž đ Stay tuned for more updates from the Allogenix project contributors: Benoit Pinteur, George Alzeeb, lionel Chalus, LĂ©a Perles, Wolfgang Moritz, Irina Agarkova, Laure-Anne Ligeon, Simon Stroebel, PhD, MichaĆ Rudnik, Maja Nedic, Marion Bavand, Marion Brun, Jan Lichtenberg, Paul Edgard ClĂ©mençon, Madhu Lal Nag, MBS PhD #colorectalcancer #consortium #partnership #biotechnology #pharma
đŹ BEHIND THE SCENE – LĂ©a Perles : Strategic Operation Lead
đŹ BEHIND THE SCENE – LĂ©a Perles (PharmD, MSc) Plongez dans lâaventure, racontĂ©e par celles et ceux qui la vivent. SEE VIDEO Dans cette interview, LĂ©a partage son parcours; et son envie d’innover en industrie #pharmaceutique dans une startup comme Brenus Pharma. En tant que chargĂ©e de Business dĂ©veloppement et Partenariats stratĂ©giques, elle met en Ćuvre la stratĂ©gie de dĂ©veloppement de Brenus, et s’implique pour faire rayonner nos #collaborations. âïžđ€ âĄïž In this interview, LĂ©a shares her career path and her desire to innovate in the #pharmaceutical industry in a startup like Brenus Pharma. As Lead of Business Development and Strategic Partnerships, she implements Brenus’ development strategy, and is committed to making our collaborations shine. #BehindTheScene #DareToInnovate CrĂ©dit vidĂ©o : https://lets-up.fr/ đCardinal Workside 60 Quai Perrache 69002 – LYON (FR)
Happy New Year 2024 !
Ready for an exciting and thrilling 2024 ! đđŁđ§Ź Toute lâĂ©quipe de Brenus Pharma vous prĂ©sente ses meilleurs voeux pour la nouvelle annĂ©e. đ LâannĂ©e 2023 a Ă©tĂ© riche en dĂ©fis, mais toujours ponctuĂ©e de fortes rencontres et dâefforts collectifs afin dâouvrir la voie pour 2024 oĂč nous souhaitons et espĂ©rons accomplir de grands succĂšs : â Lancement du premier essai clinique et inclusion des premier patients. â Scale-up industriel. â Etendre la plateforme STC avec le dĂ©veloppement dâun nouveau produit. â Renforcer les collaborations et faire rayonner la biotechnologie française. En 2024, nous continuerons de cultiver lâesprit de collaboration comme un vĂ©ritable moteur dâinnovation. đ€ Un grand merci Ă nos anciens, nouveaux et futurs partenaires, qui nous permettent de faire vivre le projet. Plus que jamais, nous continuerons dâunir nos forces. #DareToInnovate ââââââââââââââââââ The entire team of Brenus Pharma presents its best wishes for the new year. đ 2023 was a year full of challenges, but always punctuated by strong encounters and collective efforts to pave the way for 2024 where we hope to achieve great success: â Launching the first clinical trial and enrolling first patients. â Industrial scale-up. â Expanding the platform with the development of a new product. â Strengthening collaborations and promoting French biotechnology. In 2024, we will continue to foster a spirit of collaboration as a real driver of innovation. đ€ A big thank you to our former, new and future partners, who allow us to keep the project alive. More than ever, we will continue to unite our forces. #DareToInnovate #BrenusPharma #NewYear #Innovation #Healthcare #Research #Collaboration
[đąPSCC : Let’s collaborate at the heart of innovation in oncology đ]
DOWNLOAD PRESS RELEASE đ Let’s collaborate at the heart of innovation in oncology. đ Thrilled to share that Brenus Pharma is now part of the Paris Saclay Cancer Cluster (PSCC) (PSCC), the first national #Oncocluster! đ We are proud to be part of the national and European oncology innovation ecosystem. By combining PSCC’s strengths and Brenus’ technology, we aim to foster #collaborations and accelerate our shared mission to improve #patient care. âĄïž Excited to contribute to PSCC’s collective ambition in reshaping the future of oncology! đđȘ #BrenusPharma #OncologyInnovation #PSCC #NextGenerationEU
[đąStimulated Tumor Cells (STC) vaccine induces response in colorectal cancer #SITC23]
DOWNLOAD PR đŹ#SITC23 Thrilled to share new results we presented at the Society for Immunotherapy of Cancer (SITC) Congress! đ Many thanks to all contributors, CĂ©line Gongora Corentin Richard Romain Boidot Tanguy Fortin Alban Bessede Yan WANG Italiano Antoine Based on these vaccine characterization and preclinical, in-ovo and ex-vivo efficiency data, STC-1010 treatment will soon be evaluated for the first time in clinical trial in advanced metastatic stage of colorectal cancer in 2024.